Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591258 | 0.78 | GAA (0.49) | HTTGAAKDM4ETSHRLMNA | |
| SCHEMBL25836668 | 0.78 | HTT (0.42) | HTTGAAKDM4ETSHRLMNA | |
| SCHEMBL2383891 | 0.77 | HTT (0.44) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL6755229 | 0.77 | HTT (0.44) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL633115 | 0.74 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL13208612 | 0.74 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL502375 | 0.74 | HTT (0.39) | HTTGAAKDM4ETSHR | |
| SCHEMBL7100600 | 0.73 | HTT (0.41) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL9125151 | 0.73 | HTT (0.41) | HTTGAAKDM4ETSHRLMNA | |
| SCHEMBL16523107 | 0.73 | HTT (0.41) | HTTGAAKDM4ETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656971-B2 | COMT inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2938600-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20160002177-A1 | COMT INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2938600-A1 | COMT INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014102233-A1 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-03 | — | — | WO | disclosed |
| EP-1503998-B1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | COLLINS IAN J | 2008-03-20 | — | — | US | disclosed |
| US-7282513-B2 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| US-20060173054-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-08-03 | — | — | US | disclosed |
| US-7041689-B2 | Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LTD. (GB) | 2006-05-09 | — | — | US | disclosed |
| US-20050182109-A1 | Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2005-08-18 | — | — | US | disclosed |
| EP-1503998-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LTD. (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003093252-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SULFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002177-A1 | COMT INHIBITORS | COMT, PNMT, SLC6A3 | HTT 445/4885GAA 96/4885KDM4E 1308/4885 |
| US-20050182109-A1 | Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | HTT 909/4885GAA 280/4885KDM4E 3665/4885 |
| US-20060173054-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | HTT 428/4885GAA 266/4885KDM4E 4039/4885 |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | HTT 428/4885GAA 266/4885KDM4E 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.